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Chapter 1   Inroduction 
Bovine leukemia virus (BLV) is an oncogenic member of the genus Deltaretrovirus 
of the family Retroviridae (Figure 1A). It was first reported in 1871 as the presence of 
slightly yellow nodules in the enlarged spleen of a leukocytic cattle were communicated 
in the German literature by Leisering and is the etiological agent of enzootic bovine 
leukosis (EBL), which is the most common neoplastic disease of cattle. BLV is closely 
related to human T-cell leukemia viruse type 1 and 2 (HTLV-1 and -2). BLV induces 
major economic losses in cattle production and milk export in several regions of the 
world. It is encoded by genomic RNA, gag, pro, pol, and env essential genes, which are 
necessary for the production of infectious virions, two identical long terminal repeats 
(LTRs), in addition, R3, G4, tax and rex genes in the unique regulatory and accessory 
pX region (Figure 1B). 
The pathologically complex virus and host genetic factors are major determinants of 
disease progression in chronic infectious disease. During natural or iatrogenic 
transmission of BLV primarily, one of the earliest indications of infection is the onset of 
a humoral anti-viral response at about 1-8 weeks post-inoculation. Antibodies are 
produced to recognize the BLV proteins and some antibodies are directly lytic for 
BLV-producing cells (Figure 2). Besides, the level of cell-mediated immune response 
increases with progression of the disease towards the acute phase. The CD8+ T cells 
produce cytokines and antibodies to kill the infected cells or inhibit viral replication. In 
addition, a virus-dependent and a virus-independent CD4 helper T cell response are 
triggered in BLV infection. The antibodies bind to antigens at specific sites that 
correspond to the antigenic determinants or B/T cell epitopes. 
The cell-mediated and humoral immune responses to pathogen antigens are high 
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heritability with most of the genetic component mapping outside of the major 
histocompatibility complex (MHC). The MHC system in cattle is known as the bovine 
leukocyte antigen (BoLA) system. The grooves of MHC that were expressed by specific 
B lymphocytes, macrophage dendritic cells, and activated T lymphocytes, provide 
antigen peptide to CD8 and CD4 T cells. The DRB3 is the only functional locus with 
BoLA class II loci, which plays a direct role in controlling the number of BLV-infected 
peripheral B lymphocytes in vivo in Holstein and Japanese Black Cattle had been 
reported. In addition, the proviral load is a key factor in the subclinical progression of 
BLV infections. The bovine section of the Immuno Polymorphism Database 
(IPD)-MHC database (http://www. ebi.ac.uk/ipd/mhc/bola/index.html) currently 
contains 94 BoLA class I alleles and 132 BoLA-DRB3 alleles. Thus, the BoLA 
polymorphic alleles that be thought inducing individual different are must go beyond a 
major step for development BLV vaccine, disease control and diagnosis. 
Therefore, in this thesis, we performed the CD8+ cytotoxic T lymphocyte (CTL) 
epitope, CD4+ T cell epitope and B cell epitope (Figure 2) by epitope mapping with 
synthetic peptides of BLV proteins with BLV infected cattle which were carrying 
different alleles to find good candidates for BLV vaccine development and important 
implications for disease control and diagnosis. 
 
Chapter 2   Novel CD8+ CTL epitopes in BLV with cattle 
The CTL plays a key role in suppressing the progression of disease caused by BLV. T 
and B cell epitopes in BLV have been studied, but CD8+ CTL epitopes remain poorly 
understood. We used a library of 115 synthetic peptides covering the entirety of the Env 
proteins (gp51 and gp30), the Gag proteins (p15, p24, and p12), and the Tax protein of 
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BLV (Figure 3) to identify 11 novel CD8+ T cell epitopes (gp51N5, gp51N11, gp51N12, 
gp30N5, gp30N6, gp30N8, gp30N16, tax16, tax18, tax19, and tax20) (Figure 4, 5, and 
6) in four calves experimentally infected with BLV (N1, N2, S2, and S4) (Table 1). The 
number of CD8+ T cell epitopes that could be identified in each calf correlated with the 
BLV proviral load. Interestingly, among the 11 epitopes identified, only gp51N11 was 
capable of inducing CD8+ T cell-mediated cytotoxicity in all four calves (Figure 5), but 
it is not a suitable vaccine target because it shows a high degree of polymorphism 
according to the Wu-Kabat variability index (Figure 7A). By contrast, no CTL epitopes 
were identified from the Gag structural protein. In addition, several epitopes were 
obtained from gp30 and Tax, indicating that cellular immunity against BLV is strongly 
targeted to these proteins. CD8+ CTL epitopes from gp30 and Tax were less 
polymorphic than epitopes from gp51 (Figure 7B and C). Indeed, peptides tax16, tax18, 
tax19, and tax20 include a leucine-rich activation domain that encompasses a 
transcriptional activation domain, and the gp30N16 peptide contains a proline-rich 
region that interacts with a protein tyrosine phosphatase SHP1 to regulate B cell 
activation. Moreover, at least one CD8+ CTL epitope derived from gp30 was identified 
in each of the four calves. These results indicate that BLV gp30 may be the best 
candidate for the development of a BLV vaccine. 
 
Chapter 3   CD4+ T cell epitopes in BLV from cattle carrying 
susceptibility-associated BoLA class II haplotypes  
CD4 T cell epitope be known can stimulate T cell proliferation in chronic disease. 
However, the progression of BLV infection to PL is associated with reduced expression 
of classical Th1 and Th2 cytokines by CD4 T cells. The BoLA class II region plays a 
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key role in the subclinical progression of BLV infection. Specially, BoLA-DRB3 alleles 
are strongly associated with sensitivity and resistance to PL. the relation of CD4 T cell 
epitope and BoLA-DRB3 allele is still unknown. In this chapter, we examined three 
disease-susceptible Japanese Black cattle and two non-susceptible cattle; these five 
cattle (N1, N2, S2, S4, and S6) (Table1) were given BLV-infected blood and then 
subjected to CD4+ T cell epitope mapping. BLV provirus levels increased markedly in 
the two of three susceptible cattle (S2 and S6), and moderately in one susceptible cattle 
(S4) and one non-susceptible cattle (N2); however, level was reduced in the other 
non-susceptible cattle (N1) (Table1). Thirty-eight CD4+ T cell epitopes, corresponding 
to p15, p24, gp30, gp51, and Tax protein amino acid sequences of BLV, were identified 
(Figure 8, 9 and 10). Moreover, epitopes for intracellular antigens were not detected in 
disease susceptibility cattle. This result more clearly showed that antigens are restricted 
according to class II haplotype, and that genotyping is important to determine the 
antigenic epitopes recognized by the host immune response. This information will be 
useful for developing an epitope-based vaccine against BLV.  
 
Chapter 4   Common B cell epitope in BLV via high-throughput 
peptide screening system in infected cattle 
BLV is a major animal health problem worldwide, and is closely related to HTLV. B 
cell epitopes are important for the use of antibodies as therapeutic agents, the 
epitope-driven vaccine design, and immunological assays. A common B cell epitope for 
BLV has not yet been found due to individual differences in disease susceptibility. We 
used a peptide microarray with 156 synthetic 15-mer peptides covering the envelope 
glycoprotein gp51 and the Gag proteins p15, p24, and p12 (Table 2) to map B cell 
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epitope and one B cell epitope, gp51p16 (Table 2), was recognized by all four cattle 
experimentally infected with BLV (N1, N2, S4, and S6) (Table 1). A newly developed 
high-throughput peptide ELISA system revealed 590 (91.2%) of 647 cattle naturally 
infected with BLV (Figure 11), carrying 25 different BoLA-DRB3 alleles (Table 3), 
responded to a 20-mer gp51p16-C peptide containing a C-terminal cysteine and 
gp51p16. Alanine mutation and comparison of the sequences at 17 amino acid positions 
within gp51p16-C revealed that R7, R9, F10, V16, and Y18 (Figure 12) were the 
common binding sites to BLV antibodies, and two of these sites were found to be highly 
conserved (Figure 13C). Transient expression in the cells of five infectious molecular 
clones of BLV with a single alanine mutation at five common antibody binding sites 
had no effect syncytia formation of the gp51 protein. In addition, the mutant proteins, 
R7A and R9A had no effect on the expression of gp51 protein; the gp51 protein 
expressions of F10A, V16A and Y18A were lower than that of the wild type protein 
(Figure 13A and B). This is the first report to identify a common B cell epitope in BLV 
by comprehensive screening of BLV-infected cattle with varied genetic backgrounds in 
BoLA-DRB3. Our results are thought important implications for disease control and 
diagnosis. The identification and characterization of common B cell epitope of BLV is 
also a good model to develop HTLV diagnosis by immunological test. 
 
Conclusions  
Base on the upper researches, we identified CD8+ CTL epitopes, CD4+ T cell epitopes 
and B cell epitope by overlapping peptides on BLV proteins. The results are shown as 
following: 
1. Novel 11 CD8+ CTL epitopes of BLV Env and Tax proteins are identified. The 
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number of CD8+ CTL epitopes correlated with the proviral load in BLV-infected 
cattle. However, no CD8+ CTL epitope was found from BLV Gag proteins. 
According to Wu-Kabat index results, the surface glycoprotein gp51 is not a suitable 
vaccine target. The transmembrane protein gp30 is the best candidate for BLV 
vaccine development. 
2. We found 38 BLV CD4+ T cell epitopes from five cattle including four kinds of 
BoLA class II genotype. CD4+ T cell epitope for intracellular antigens were not 
detected in disease susceptible cattle. The results of CD4+ T cell epitopes clearly 
showed that antigens are restricted according to BoLA class II haplotype. 
3. One common B cell epitope was identified on BLV Gag proteins and gp51 protein 
and it contains five common binding sites which are amino acid R7, R9, F10, V16 
and Y18. These five binding sites have no effect syncytia formation of the gp51 
protein. In addition, the mutant proteins, R7A and R9A had no effect on the 
expression of gp51 protein; the gp51 protein expressions of F10A, V16A and Y18A 
were lower than that of the wild type protein. 
These upper results showed that transmembrane protein gp30 is firstly known the best 
target region to development a BLV vaccine that could induce cell-mediated immunity 
in the stage of BLV infection, and the expression of Th cells in BLV infection is linked 
to the polymorphism in the BoLA-DRB3 allele, and the identified common B cell 
epitope is a good candidate to design epitope-driven vaccine and is an important 
information to disease control and diagnosis. 
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Figure 1. Schematic 
representation of the 
viral particle (A) and 
genome organization 
(B) of BLV. The 
virus model from 
Riken, Tsukuba, 
taken by Bai L. BLV 
encodes a unique 
regulatory and 
accessory protein in 
the pX region. 
Figure 2. The images 
of antigen recognition 
in viral infectious 
diseases. 
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Table 1. Japanese black cattle examined in the study. 
Animal  BoLA class II BoLA class 1 Allelec Proviral loadd Breed Age Sex WBCse PBLsf Antibodies 
No. DRB3 allelea A:B DQA1 alleleb A:B  (CoCoMo-qPCR-2)  (month)  (cells/μl) (cells/μl)  to BLV
g 
N1 2703:1501 10011:0204 N*02604 72h Japanese black 6 ♀ 7480h 4520h + 
    
263i 
 
9 
 
7,580i 4210i + 
    
149j 
 
6 
 
8250j 4900j + 
N2 0503:1501 10011:0101 N*02604 67729h Japanese black 6 ♀ 13500h 9250h + 
    50877
i  9  16000
i 10200i + 
    
58176j 
 
6 
 
12100j 9140j + 
S2 1601:1601 10012:10012 N*02701 76839h Japanese black 8 ♂ 14100h 8820h + 
    96232i 
 
10 
 
15900i 11600i + 
    15100  8  15100 10700 + 
S4 1601:1601 10012:12021 N*02702 58501h Japanese black 7 ♂ 13400 h 8650h + 
    
76029i 
 
9 
 
14200i 10400i + 
    67284j 
 
8 
 
15500j 11100j + 
S6  1601:1601 10012:10012 ND 80797 Japanese black 7 ♂ 12500 9200 + 
    
100377i 
 
9 
 
10200i 10200i + 
    93456j 
 
6 
 
13900j 9570j + 
a,b BoLA-DRB3 alleles and BoLA-DQA1 alleles were typed by PCR-sequence-based typing (SBT) method. 
c BoLA class1 alleles are according to the BoLA nomenclature committee of the IPD–MHC database, calves N1 and N2 carried allele (GenBank accession 
no. LC055984) which is identical to the previously reported allele, BoLA-N*02604, S4 carried a novel allele, BoLA-N*02701 (GenBank accession no. 
LC055985), and S4 carried allele (GenBank accession no. LC055986) which is identical to the previously reported allele, BoLA-N*02702. 
The amino acid sequences of BoLA class were determined from cDNA clone sequences using the pGEM®-T Easy Vector System. The allele was 
considered one of the predominantly expressed types in each experiment animal. ND: Not Determined. 
d Proviral load (expressed as the number of copies of provirus per 105 peripheral blood mononuclear cells) was evaluated using CoCoMo-qPCR-2 method. 
e White blood cells (WBCs) were measured at a single time point in all calves during the each experiment. 
f Peripheral blood lymphocytes (PBLs) were measured at a single time point in all calves during the each experiment. 
g ELISA (enzyme-linked immunosorbent assay) to detect anti-BLV antibodies was performed using the BLV ELISA kit. 
 +, BLV positive serum. 
h Blood samples were used for identification of CD8+ CTL epitope experiment.  
i Blood samples were used for identification of CD4+ T cell epitope experiment. 
j Blood samples were used for identification of B cell epitope experiment. 
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Figure 3. Synthetic peptides of 20-mer overlapping peptides corresponding to the Gag (p15, p24, 
and p12), Env (gp51 and gp30) and Tax proteins. These overlapping peptides were made against 
each mature peptide encoded and expressed by genes in env, gag, and tax, which sequences of BLV 
Gag (GenBank accession no. LC057268), Env (GenBank accession no. EF600696), and Tax 
(GenBank accession no. EF600696) were reported. (A) Schematic representation of BLV genome 
organization and viral proteins. (B) The pool, name, sequence and amino acid positions of peptide 
are shown in column (left to right). The pool contains five individual peptides. a15 amino acids in 
length; b19 amino acids in length; and c18 amino acids in length. 
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Figure 4. CD8+ T cell proliferative responses to 23 peptide pools. CD8+ T cells were separated from 
PBMCs from four BLV-infected calves [N1 (A), S4 (B), N2 (C), and S2 (D)] and used as effector 
cells. CD8- T cells were treated with 50 µg/ml mitomycin C for 60 min at 37°C and used as APCs. 
CD8+ T cells (1 × 105 cells/50 µl) and CD8- T cells (1 × 105 cells/50 µl) were treated with 80% 
DMSO (negative control) or with 23 peptide pools, each containing five individual peptides at 20 
µM of each peptide. After incubation for 109 h at 37°C, the CD8+ T cell proliferation responses were 
examined in a WST-8 assay. The bars represent the mean ± the standard deviation (S.D.) of triplicate 
wells. 
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Figure 5. CD8+ T cell 
proliferative responses to 
individual peptides within 
positive peptide pools. CD8+ 
T cells (effector cells; 1 × 105 
cells/50 µl) from four 
BLV-infected calves [N1 (A), 
S4 (B), N2 (C), and S2 (D)] 
and CD8- T cells (APCs; 1 × 
105 cells/50 µl) were treated 
with mitomycin C and 
incubated with 80% DMSO 
(negative control) or 20 µM 
of each peptide from pools 9, 
10, 11, 13, 14, 15, and 21 for 
calf N1, pools 8, 9, 11, 14, 
and 21 for calf S4, pools 9, 
11, 14, 20, and 21 for calf 
N2, and pools 9, 13, 14, 15, 
and 21 for calf S2. The cells 
were treated with peptide for 
109 h at 37°C and the CD8+ 
T cell proliferation responses 
were examined in a WST-8 
assay. The bars represent the 
mean ± standard deviation 
(S.D.) of triplicate wells. 
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Figure 6. Cytotoxic activity of CD8+ cytotoxic T cells against autologous PBMCs in response to 
peptides. These peptides had CD8+ T cell proliferative response in the WST-8 assay. CD8+ T cells 
(effector cells, EC) were separated from PBMCs from four BLV-infected calves [N1 (A), S4 (B), N2 
(C), and S2 (D)] and incubated with autologous PBMCs (target cells, TC) with different 
concentrations of peptide (0, 0.5, 5, or 20 µM), and the cytotoxic activity of the CD8+ T cells was 
examined in a CytoTox96 non-radioactive cytotoxicity assay. N1 was tested at an EC:TC ratio of 
10:1, while S4, N2 and S2 were used at an EC:TC ratio of 20:1. The bars represent the mean ± 
standard deviation (S.D.) of triplicate wells. Significant differences between the groups are indicated 
by asterisks (*p < 0.05, **p < 0.01, and ***p < 0.001). 
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Figure 7. Wu-Kabat variability index of the CD8+ CTL epitopes on all sequences of gp51, gp30, and 
Tax. The 517 sequences of gp51, 118 sequences of gp30, and 90 sequences of Tax were obtained 
from the GenBank database. The vertical axis indicates the Wu-Kabat index at each amino acid 
position and the horizontal axis shows the amino acid positions. (A) The Wu-Kabat index of the 
gp51 region (amino acids 1-301). Red, blue, and yellow blocks indicate the CD8+ CTL epitopes 
gp51N5, gp51N11, and gp51N12, respectively. (B) The Wu-Kabat index of the gp30 region (amino 
acids 302–515). The blue, brown, green, and pink blocks indicate the CD8+ CTL epitopes gp30N5, 
gp30N6, gp30N8, and gp30N16, respectively. (C) The Wu-Kabat index of Tax region (amino acids 
1–309). The blue, red, green, and pink blocks indicate the CD8+ CTL epitopes tax16, tax18, tax19, 
and tax20, respectively. (D) The sequences and Wu-Kabat index at each position of the CD8+ CTL 
epitopes. 
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Figure 8. CD4+ T cell 
proliferative responses to 23 
peptide pools. PBMCs were 
obtained from five BLV-infected 
cattle (S2, S4, S6, N2, and N1). 
CD4+ T cells were then isolated 
and used as effector cells. 
PBMCs were pre-treated with 
mitomycin C (4 × 105/50 µl; 50 
µg/ml) for 1 h at 37°C and then 
co-incubated with CD4+ T cells 
(1 × 105/50 µl) and different 
peptide pools (each pool 
contained five different peptides, 
each at 20 μM) for 113 h at 
37°C/5% CO2. Cell Counting 
Kit-8 was used to measure CD4+ 
T cell proliferation. The 
absorbance of the test wells was 
compared with that of control 
wells that did not contain 
peptides. The Stimulation Index 
(S.I.) was calculated as follows: 
S.I. = [(PBMC+CD4+peptide)- 
(Medium only)]/[(PBMC+CD4)- 
(Medium only)]. The bars 
represent the mean ± standard 
deviation (S.D.) of triplicate 
wells. Asterisk and shade box 
bar means the pool showed 
significantly higher value than 
DMSO well (p < 0.05). 
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Figure 9. CD4+ T cell proliferative responses to individual peptides within positive peptide pools. 
CD4+ T cells (effector cells; 1 ×105 cells/50 µl) from four BLV-infected cattle (S2, S6, N2, and N1) 
were co-incubated with mitomycin C-treated PBMCs (APCs; 4 × 105 cells/50 µl) and incubated with 
either 80% DMSO (negative control) or peptide from pools 9, 11, 14, and 20 (for S2), pools 9, 11, 12, 
and 21 (for S6), pools 9, 14, and 21 (for N2), and pools 9 and 21 (for N1), all at a final concentration 
of 20 μM. The cells were incubated with peptide for 113 h at 37°C and CD4+ T cell proliferation was 
examined using Cell Counting Kit-8. The absorbance of the test wells was compared with that of 
control wells incubated without peptide and the Stimulation index (S.I.) was calculated as follows: 
S.I. = [(PBMC+CD4+peptide)-(Medium only)]/[(PBMC+CD4)-(Medium only)]. The bars represent 
the mean ± standard deviation (S.D.) of triplicate wells. Asterisk and shade box bar means the pool 
showed significantly higher value than DMSO well (p < 0.05). 
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MGNSPSYNPP AGISPSDWLN LVQSAQRLNP RPSPSDFTDL KNYIHWFHKT QKKPWTFTSG GPTSCPPGRF GRVPLVLATL
NEVLSNEGGA PGASAPEEQP PPYDPPAI
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SLCPTINEPC CFLRIQNDSI IRLGDLQPLS QRVSTDWQWP WNWDLGLTAW VRETIHSVLS LFLLALFLLF LAPCLIKCLT
SRLLKLLRQA PHFPEISLTP KPDSDYQALL PSAPEIYSHL SPVKPDYINL RPCP
Gp30-Transmembrane
WRCSLSLGNQ QWMTAYNQEA KFSISIDQIL EAHNQSPFCA KSPRYTLDSV NGYPKIYWPP PQGRRRFGAR AMVTYDCEPR
CPYVGADRFD CPHWDNA QCH GIFTLTWEIW GYDPLITFSL HKIPDPPQPD FPQLNSDWVPSQA DQGSFYVNHQ ILFLHLK
SVRSWALLLN QTARAFPDCA ICWEPSPPWA PEILVYNKTI SSSGPGLALP DAQIFWVNTS SFNTTQGWHH PSQRLLFNVS
QGNALLLPPI SLVNLSTASS APPTRVRR
LPIISEGNRN RHRAWALREL QDIKKEIENK APGSQVWIQT LRLAILQADP TPADLEQLCQ YIASPVDQTA HMTSLTAAIA
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PVSL LRKVL ILNQMANFSL LPSFDTLLVD PLRLSVFAPDSPFERS PFQPYQCQLP SASSDGCPII GHGLLPWNNL VTHPV
TRGAIRYLST LLTLCPATCI LPLGEPFSPN VPICRFPRDS NEPPLSEFEL PLIQTPGLSW SVPAIDLFLT GPPSPCDRLH
VWSSPQALQR FLHDPTLTWS ELVASRKIRL DSPLKLQLLE NEWLSRLF
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Figure 10. Schematic representation of CD4+ T cell epitopes based on the deduced amino acid 
sequences of the BLV p15, p24, gp30, gp51, and Tax proteins. The peptide name and arrow denote 
the CD4+ T cell epitopes identified in this chapter. Box under each arrow showed the cattle name 
which detected the corresponding epitope. Colored box means positive for corresponding cattle 
number, and white box means negative. The order and color of each box which corresponding to 
each cattle were shown at bottom of figure. Boldface type denotes CD4+ T cell epitopes previously 
reported by Gatei et al. (Gatei et al., 1993) and Sakakibara et al. (Sakakibara et al., 1998). A 
membrane-spanning domain, an immunosuppressive domain, a binding region within the surface 
unit (SU), a proline-rich region upstream of the immunoreceptor tyrosine-based activation motifs 
(ITAMs), and immunoreceptor tyrosine-based inhibition motifs (ITIMs) in the gp30 protein are 
shown, along with a leucine-rich activation domain in the Tax protein. 
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Table 2. The comparison results of four cattle samples for a peptide microarray. 
 Peptide 
Sequence 
Cattle
b 
No.   Peptide 
Sequence 
Cattle
b 
No.   Peptide 
Sequence 
Cattle
b 
No. 
No. S4 S6 N1 N2  No. S4 S6 N1 N2  No. S4 S6 N1 N2 
p15
a
       p24
a
       gp51
a
      
1 MGNSPSYNPPAGISP - + + -  28 DLRSQYQNLWLQAWK - + - -  12 RYTLDSVNGYPKIYW - - - + 
2 PSYNPPAGISPSDWL - - + -  29 QYQNLWLQAWKNLPT - - - -  13 DSVNGYPKIYWPPPQ - - - - 
3 PPAGISPSDWLNLVQ - - - -  30 LWLQAWKNLPTRPSV - - - -  14 GYPKIYWPPPQGRRR - + - - 
4 ISPSDWLNLVQSAQR + - - -  31 AWKNLPTRPSVQPWS - - - -  15 IYWPPPQGRRRFGAR + + + - 
5 DWLNLVQSAQRLNPR - - - +  32 LPTRPSVQPWSTIVQ + - - -  16 PPQGRRRFGARAMVT + + + + 
6 LVQSAQRLNPRPSPS - - - -  33 PSVQPWSTIVQGPAE - - + -  17 RRRFGARAMVTYDCE - + + + 
7 AQRLNPRPSPSDFTD - - - -  34 PWSTIVQGPAESYVE - - - -  18 GARAMVTYDCEPRCP + - - - 
8 NPRPSPSDFTDLKNY - - - -  35 IVQGPAESYVEFVNR - - - -  19 MVTYDCEPRCPYVGA - - - - 
9 SPSDFTDLKNYIHWF - - - +  36 PAESYVEFVNRLQIS - + - -  20 DCEPRCPYVGADRFD - - - - 
10 FTDLKNYIHWFHKTQ - - - +  37 YVEFVNRLQISLADN - - - -  21 RCPYVGADRFDCPHW - - - - 
11 KNYIHWFHKTQKKPW - - - -  38 VNRLQISLADNLPDG - + - -  22 VGADRFDCPHWDNAS - - - - 
12 HWFHKTQKKPWTFTS - - - -  39 QISLADNLPDGVPKE - + + +  23 RFDCPHWDNASQADQ - - - - 
13 KTQKKPWTFTSGGPT - - - -  40 ADNLPDGVPKEPIID - - + -  24 PHWDNASQADQGSFY - - - - 
14 KPWTFTSGGPTSCPP - - - -  41 PDGVPKEPIIDSLSY - - - -  25 NASQADQGSFYVNHQ - - - - 
15 FTSGGPTSCPPGRFG - - - -  42 PKEPIIDSLSYANAN - - + -  26 ADQGSFYVNHQILFL - - - - 
16 GPTSCPPGRFGRVPL - - - -  43 IIDSLSYANANKECQ - - + -  27 SFYVNHQILFLHLKQ - - - - 
17 CPPGRFGRVPLVLAT - - - -  44 LSYANANKECQQILQ - - + -  28 NHQILFLHLKQCHGI - - - - 
18 RFGRVPLVLATLNEV - - - +  45 NANKECQQILQGRGL - - + -  29 LFLHLKQCHGIFTLT - - - - 
19 VPLVLATLNEVLSNE - - - -  46 ECQQILQGRGLVAAP - - - -  30 LKQCHGIFTLTWEIW - - + - 
20 LATLNEVLSNEGGAP - + + -  47 ILQGRGLVAAPVGQK - + - -  31 HGIFTLTWEIWGYDP - + + - 
21 NEVLSNEGGAPGASA - - - -  48 RGLVAAPVGQKLQAC - - - -  32 TLTWEIWGYDPLITF - - + + 
22 SNEGGAPGASAPEEQ - - - -  49 AAPVGQKLQACAHWA - - - -  33 EIWGYDPLITFSLHK - - - - 
23 GAPGASAPEEQPPPY - - + -  50 GQKLQACAHWAPKMK - - - -  34 YDPLITFSLHKIPDP - - + - 
24 ASAPEEQPPPYDPPA - - - -  51 QACAHWAPKMKQPAI - - - -  35 ITFSLHKIPDPPQPD - + - - 
25 EEQPPPYDPPAI - - + -  52 HWAPKMKQPAIL - - - -  36 LHKIPDPPQPDFPQL - - - - 
p24
a
 
      p12
a
 
      37 PDPPQPDFPQLNSDW - - + - 
            38 QPDFPQLNSDWVPSV - - - - 
1 LPIISEGNRNRHRAW + - + -  1 VHTPGPKMPGPRQPA + + + -  39 PQLNSDWVPSVRSWA - - - - 
2 SEGNRNRHRAWALRE + - + -  2 GPKMPGPRQPAPKRP - - - -  40 SDWVPSVRSWALLLN - + + - 
3 RNRHRAWALRELQDI + + + -  3 PGPRQPAPKRPPPGP - - - -  41 PSVRSWALLLNQTAR - - - - 
4 RAWALRELQDIKKEI + + + -  4 QPAPKRPPPGPCYRC - - - -  42 SWALLLNQTARAFPD - - + - 
5 LRELQDIKKEIENKA + + + -  5 KRPPPGPCYRCLKEG - - - -  43 LLNQTARAFPDCAIC - - - - 
6 QDIKKEIENKAPGSQ + - + -  6 PGPCYRCLKEGHWAR - - - -  44 TARAFPDCAICWEPS - - - - 
7 KEIENKAPGSQVWIQ + - + -  7 YRCLKEGHWARDCPT - - - -  45 FPDCAICWEPSPPWA - - - - 
8 NKAPGSQVWIQTLRL - - + -  8 KEGHWARDCPTKATG - + + +  46 AICWEPSPPWAPEIL - - - - 
9 GSQVWIQTLRLAILQ - - - -  9 WARDCPTKATGPPPG - + + +  47 EPSPPWAPEILVYNK - - - - 
10 WIQTLRLAILQADPT - - - -  10 CPTKATGPPPGPCPI + - + -  48 PWAPEILVYNKTISS - - - - 
11 LRLAILQADPTPADL + - - -  11 ATGPPPGPCPICKDP - - - -  49 EILVYNKTISSSGPG - - - - 
12 ILQADPTPADLEQLC + - - -  12 PPGPCPICKDPSHWK + + + -  50 YNKTISSSGPGLALP - - - - 
13 DPTPADLEQLCQYIA + - - -  13 CPICKDPSHWKRDCP - - - -  51 ISSSGPGLALPDAQI - - - - 
14 ADLEQLCQYIASPVD - - + -  14 KDPSHWKRDCPTLKS - + + -  52 GPGLALPDAQIFWVN - + - + 
15 QLCQYIASPVDQTAH + - + -  gp51
a
 
      53 ALPDAQIFWVNTSSF - - - - 
16 YIASPVDQTAHMTSL - - + -        54 AQIFWVNTSSFNTTQ - - + - 
17 PVDQTAHMTSLTAAI - - - -  1 TWRCSLSLGNQQWMT - - - -  55 WVNTSSFNTTQGWHH - - - - 
18 TAHMTSLTAAIAAAE - - - -  2 SLSLGNQQWMTAYNQ - - - -  56 SSFNTTQGWHHPSQR - - + - 
19 TSLTAAIAAAEAANT + - + -  3 GNQQWMTAYNQEAKF - - - -  57 TTQGWHHPSQRLLFN - - + - 
20 AAIAAAEAANTLQGF - - - -  4 WMTAYNQEAKFSISI - - + -  58 WHHPSQRLLFNVSQG - - - - 
21 AAEAANTLQGFNPQN - - + -  5 YNQEAKFSISIDQIL - - - -  59 SQRLLFNVSQGNALL - - - - 
22 ANTLQGFNPQNGTLT - - - +  6 AKFSISIDQILEAHN - - + -  60 LFNVSQGNALLLPPI - - + - 
23 QGFNPQNGTLTQQSA - - + -  7 ISIDQILEAHNQSPF - - + -  61 SQGNALLLPPISLVN - - + - 
24 PQNGTLTQQSAQPNA - - + -  8 QILEAHNQSPFCAKS + - - -  62 ALLLPPISLVNLSTA - - + - 
25 TLTQQSAQPNAGDLR - - + -  9 AHNQSPFCAKSPRYT - - - -  63 PPISLVNLSTASSAP - - - - 
26 QSAQPNAGDLRSQYQ - - + -  10 SPFCAKSPRYTLDSV - - - -  64 LVNLSTASSAPPTRV - - + - 
27 PNAGDLRSQYQNLWL - + - -  11 AKSPRYTLDSVNGYP - - - -  65 STASSAPPTRVRR - - - - 
a Antigens were derived from BLV Gag (p15, p24, and p12) and Env gp51 proteins. 
b These BLV positive serums were obtained from BLV-experimentally infected cattle as shown in 
Table 1. 
+, only positive response with BLV positive serum; -, none response with serums. 
The grey shade indicates a common B cell epitope which was identified in four BLV experimentally 
infected Japanese Black cattle by peptide microarray. 
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Table 3. The serumsa used in a new peptide ELISA high-throughput system. 
Local Farm  BLV positive samplesb  BLV negative samplesc 
no. Cattle BoLA-DRB3  Cattle BoLA-DRB3 
 no. No. Alleles  no. No. Alleles  
Aichi 2 32 12 0101, 0201, 0502, 0503, 0701, 
0902, 1001, 1101, 14011, 1501, 
1601, 1801 
 5 6 0201, 0503, 1101, 1302, 
1501, 1601 
Ishikawa 1 12 7 0101, 0201, 0902, 1001, 1101, 
1201, 1501 
 3 5 0601, 1101, 1201, 1501, 
2703 
Iwate 2 47 14 0101, 0201, 0502, 0503, 0701, 
0902, 1001, 1101, 1201, 14011, 
1501, 1601, 2703, 4401 
 14 7 0503, 1001, 1101, 1201, 
14011, 1501, 1601 
Oita 2 30 13 0101, 0201, 0301, 0503, 0701, 
0801, 0902, 1001, 1101, 1302, 
1501, 1601, 2703 
 8 7 0101, 0201, 0301, 1001, 
1101, 1201, 2703 
Osaka 2 52 12 0101, 0201, 0701, 0902, 1001, 
1101, 1201, 14011, 1501, 1601, 
1801, 2703 
 2 4 0101, 1101, 14011, 1501 
Okinawa 2 43 12 0101, 0201, 0502, 0503, 0701, 
0902, 1001, 1101, 1201, 14011, 
1501, 1601 
 19 10 0101, 0201, 0503. 0701, 
1001, 1101, 1201, 14011, 
1501, 1601 
Kagoshima 2 9 7 0502, 0503, 0701, 1001, 1302, 
1501, 1601 
 28 10 0101, 0502, 0503, 0801, 
1001, 1101, 1201, 1302, 
14011, 1501, 1601, 2703  
Kanagawa 2 55 11 0101, 0201, 0701, 0902, 1001, 
1101, 1201, 14011, 1501, 1801, 
2703 
 10 8 0101, 0902, 1001, 1101, 
1201, 14011, 1501, 2703  
Gifu 3 67 17 0101, 0201, 0501, 0502, 0503, 
0701, 0801, 0902, 1001, 1101, 
1201, 1302, 14011, 1501, 1601, 
1801, 2703 
 1 2 0101, 1001 
Nagano 2 14 12 0101, 0501, 0502, 0901, 0902, 
1001, 1101, 1201, 14011, 1501, 
1601, 1801 
 7 2 0101, 0902, 1001, 1101, 
14011, 1601, 2703 
Shiga 2 24 10 0101, 0601, 0902, 1001, 1101, 
1201, 14011, 1501, 1801, 2703 
 5 6 0101, 1001, 1101, 1201, 
14011, 2703 
Shizuoka 3 47 12 0101, 0201, 0503, 0901, 0902, 
1001, 1101, 1201, 14011, 1501, 
1601, 2703 
 13 10 0101, 0502, 0503, 0701, 
0902, 1001, 1101, 1201, 
1501, 1601 
Hyogo 2 37 11 0101, 0201, 0902, 1001, 1101, 
1201, 14011, 1501, 1601, 1801, 
2703 
 30 10 0101, 0201, 0901, 0902, 
1001, 1101, 1201, 14011, 
1501, 1601, 1801, 2703  
Chiba 2 45 13 0101, 0201, 0601, 0902, 1001, 
1101, 1201, 14011, 1501, 1601, 
1701, 1801, 2703 
 16 12 0101, 0601, 0701, 0902, 
1001, 1101, 1103, 14011, 
1501, 1701, 2703, 3201 
Tokyo 1 16 6 0101, 1001, 1101, 14011, 1501, 
1801 
 15 10 0101, 0902, 1001, 1101, 
1201, 14011, 1501, 1601, 
1801, 2703 
Nagasaki 2 22 11 0101, 0503, 0601, 0701, 0902, 
1001, 1101, 1201, 14011, 1501, 
1601 
 43 16 0101, 0201, 0502, 0503, 
0601, 0701, 0801, 0902, 
1001, 1101. 1201, 14011, 
1501, 1601, 2703, 3401 
Niigata 2 42 15 0101, 0502, 0503, 0504, 0701, 
0902, 1001, 1101, 1201, 14011, 
1501, 1601, 2002, 2703, 3401 
 15 14 0101, 0502, 0503, 0701, 
0902, 1001, 1101, 1103, 
1201, 1302, 14011, 1501 
1601, 2802 
Hokkaido 1 9 9 0101, 0201, 0502, 0503, 1001, 
1201, 14011, 1601, 3401 
 5 6 0502, 0503, 1001, 1201, 
1501, 1601 
Mie 1 3 4 0101, 1001, 1101, 1501  20 11 0101, 0201, 0503, 1001, 
1101, 1201, 1302, 14011, 
1501, 1601, 1701 
Yamagata 2 41 10 0101, 0502, 0503, 0701, 1001, 
1201, 14011, 1501, 1601, 2703 
 11 9 0201, 0502, 0701, 0801, 
1001, 1101, 1201, 1501, 
1601 
Total 38 647    270   
a Serum samples were obtained from 647 BLV-naturally infected cattle which were positive for 
anti-BLV antibodies and BLV provirus as determined by an anti-BLV ELISA kit and a 
BLV-CoCoMo-qPCR-2 assay, respectively, and 270 BLV uninfected cattle.  
b These BLV positive samples had 25 different BoLA-DRB3 alleles that were typed by PCR-SBT 
method.. 
c These BLV negative samples had 23 different BoLA-DRB3 alleles, which 20 alleles of them were 
same with identification alleles on BLV positive samples as described above (b).  
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Figure 11. Figure 13. Results of the analyses of gp51p16-C with BLV positive and negative serums 
via a new high-throughput peptide ELISA system. (A) The define line of positive response. It was an 
OD value of 0.3 that was determined in accordance to histogram analysis using BLV negative and 
positive sera. (B) The response of gp51p16-C with positive serum from 647 cattle naturally infected 
with BLV by ELISA. Serum samples collected from 647 cattle naturally infected with BLV were 
observed to have different levels of proviral loads and shared 25 different BoLA-DRB3 alleles. The 
average and standard deviation of infected samples by new peptide ELISA were 0.96 and 0.54, 
respectively (C) The summary of responses of gp51p16-C in 647 serum samples from cattle 
naturally infected with BLV. (D) The response of gp51p16-C with negative serum from BLV 
non-infected 270 cattle. Serum samples collected from BLV non-infected 270 cattle shared 23 
different BoLA-DRB3 alleles. The average and standard deviation of non-infected samples were 
0.12 and 0.16, respectively. (E) The summary of responses of gp51p16-C in 270 serum samples from 
BLV non-infected cattle. 
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Figure 12. Response of BLV positive serum with single alanine variants of gp51p16-C via a new 
high-throughput peptide ELISA system. (A) Sequences of the gp51p16-C peptide and its variants 
with single alanine mutations are shown in the single-letter amino acid code, and alanine mutation 
sites are represented in red. (B) The stimulation index (SI) of four BLV positive serum samples was 
obtained from cattle experimentally infected with BLV (S4, S6, N1, and N2) for individual variants. 
(C) Reactions of the serum samples obtained from cattle naturally infected with BLV for individual 
variants. 
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Figure 13. Effect of alanine 
substitutions in gp51p16-C of 
pBLV-IF on viral expression and 
fusogenicity, and conservation of 
each residue. After transfection, 
pBLV-IF, mutated pBLV-IFs with 
single alanine mutations (R7A, R9A, 
F10A, V16A, and Y18A), or a 
negative control vector and the GFP 
expression vector pEGFP-N1 were 
performed Western blotting (A) and 
syncytium (B) analyses. GFP was 
used as the reporter molecule for 
discrimination between transfected 
and untransfected cells. (A) For 
Western blotting, a fraction of 
23CLN cells were harvested 20 h 
following transfection and were 
analyzed for the ratio of 
GFP-expressing cells by flow 
cytometry. The remaining 23CLN 
cells were lysed 48 h after 
transfection, and lysates with equal 
numbers of GFP-expressing cells 
were subjected to Western blotting 
using anti-BLV Env protein and 
anti-Gag protein monoclonal 
antibodies and HRP-conjugated goat 
antibodies. FLK-BLV cells, which 
were productively infected with 
BLV, were used as the positive 
control. Positions of protein marker 
and BLV glycoprotein (gp51) were 
indicated and BLV Gag protein 
(p24). (B) For syncytium formation, 
293T cells were visualized by 
confocal laser scanning microscopy. 
(C) Distribution of polymorphic and 
frequencies of antibody binding 
amino acid residues in gp51p16-C. 
BLV nucleotide sequences (n=517) 
were collected from GenBank, and 
amino acid sequences corresponding 
to gp51p16-C were aligned. The 
amino acid positions 7, 9, 10, 16, 
and 18 are indicated by triangle. A 
single letter above gp51p16-C 
sequences indicates a polymorphic 
amino acid residue. 
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